This article is sponsored by Standard BioTools. Neurodegenerative diseases affect more than 57 million people globally, a figure expected to double within two decades1,2. This alarming projection reflects three major clinical challenges: difficulty diagnosing disease in early, treatable stages; a lack of curative therapies; and limited treatment options2,3. Read More
PLL Therapeutics will present its strategic approach in the early detection and treatment of Amyotrophic Lateral Sclerosis (ALS), a form of motor neuron disease (MND), at the 19th Bioshares Biotech Summit. Bioshares is an Australian biotech stock report. The summit, hosting emerging life science companies listed on the ASX, with… Read More
DDW’s Megan Thomas speaks with Dr Maria-Magdalena Patru, Scientific Partner at Roche Diagnostics US, about how advances in Alzheimer’s disease (AD), particularly blood-based biomarkers (BBM), can enable earlier, more accurate, and accessible detection of the disease, supporting timely treatment and improved patient outcomes. MT: Why is improving AD diagnostics crucial… Read More
